ð é«åžçç
ð äžé éé»
- è: 4 species
- S. dysenteriae (group A) â most virulent, Shiga toxin â HUS; rare 髿åŸ, endemic Africa/Asia
- S. flexneri (group B) â éçŒäž main
- S. boydii (group C) â rare
- S. sonnei (group D) â high-income main
- Gram - rod, non-motile, lactose - (most), H2S -, lysine decarboxylase -
- è¶
low infectious dose (10-100 organisms) â æ person-person
- èšåº: æ¥ dysentery (è¡ + mucus 䟿, ç, é« cramping, tenesmus)
- Risk: å
ç«¥ (daycare), travelers, MSM (oral-anal), institutional, fecal-oral
- Treatment: Azithromycin or ceftriaxone; FQ resistance â in é« risk groups (MSM)
- Complications: HUS (S. dysenteriae 1, Shiga toxin), toxic megacolon, reactive arthritis, encephalopathy (Ekiri syndrome å
ç«¥)
1ïžâ£ 现èåž
- Shigella spp. â gram - rod, åæ°§ selectivelly
- Closely related to E. coli (genetic ~ 99% identity â same species really)
- Non-motile (vs Salmonella motile)
- Lactose - (most, S. sonnei delayed +)
- Acid-tolerant â survives stomach
- Very low ID50 (10-100 organisms) â æ fecal-oral spread
Virulence
- Type III secretion (invasion + escape into cytoplasm)
- Actin-based motility (cell-to-cell, like Listeria)
- Shiga toxin (Stx) â S. dysenteriae 1 äž»èŠ, similar to STEC (E. coli O157)
- Endotoxin systemic
2ïžâ£ èšåºè¡šçŸ
A. Acute Bacillary Dysentery
- æœäŒ 1-3 d (short)
- Watery diarrhea å
(~ 24 hr) â dysentery (è¡ + mucus 䟿, mucus, tenesmus, painful straining)
- é« cramping abdominal pain
- Fever ⥠39°C
- Lasts 3-7 d (self-limit if mild)
B. Severe / Complications
- Toxic megacolon, perforation
- HUS (S. dysenteriae 1, Shiga toxin)
- Reactive arthritis (HLA-B27 +, âReiterâsâ) 1-4 wk after
- Encephalopathy (Ekiri syndrome å
ç«¥; convulsion, coma â mortality)
- Dehydration (especially children)
C. Carrier State
- Mild infections â asymptomatic shedding æžé±
- äž chronic carriers like Typhoid
3ïžâ£ æµè¡ç
åž
- Global ~ 200 million ç
äŸ /yr, 200,000 æ»äº¡ (most pediatric)
- High-income: S. sonnei, person-person spread; daycare, schools, MSM, travelers
- Low-income: S. flexneri + dysenteriae, food/water-borne, poor sanitation
- MSM + STI-associated: extensive outbreaks (CDC, EU) â multi-drug R
- Daycare: low ID = explosive outbreak
- Institutional (LTC, prison)
4ïžâ£ 蚺æ·
- Stool culture (selective media â XLD, Hektoen, MAC)
- GI PCR panel (BioFire FilmArray) â increasingly first-line
- Fecal lactoferrin / WBC +
- éå ± (notifiable)
5ïžâ£ æ²»ç
A. Hydration (cornerstone)
B. Antibiotic
- é©å all confirmed (vs Salmonella healthy adult äžå¿
)
- Azithromycin 500 mg PO qd à 3d (preferred for MSM-associated multi-R + Asia FQ-R)
- Ceftriaxone 2 g IV qd à 5d (severe / pediatric)
- Ciprofloxacin 500 mg bid à 3d (where susceptible)
- TMP-SMX (where susceptible)
- Pediatric / pregnant: azithromycin, ceftriaxone
C. Avoid
- Loperamide in severe dysentery â toxic megacolon risk
- NSAID â perforation risk
- Antimotility avoided å€ dysentery
D. HUS
- Supportive
- äž antibiotic (controversial in Shigella â some studies donât show worsening like STEC E. coli, but caution)
E. Carrier
- éåžž self-resolves
- Reculture stool 2-4 wk post-rx
6ïžâ£ Prevention
- Hand hygiene
- Food / water safety
- å
ç«¥ daycare exclusion until 2 - stool cultures
- MSM education
- NO vaccine routinely available (research vaccines underway â Sf2a, Wraps)
- Outbreak: PFGE / WGS for tracking; AST ç£æž¬